Get started
Author

John C. Maffeo

Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study
2023 · Mark D. Tyson, David Morris, et al. · The Journal of Urology · 37
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
2022 · Siamak Daneshmand, Iris S.G. Brummelhuis, et al. · Urologic Oncology Seminars and Original Investigations · 35
PDF
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association–defined Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: A Phase 1b Study
2024 · F. Johannes P. van Valenberg, Antoine G. van der Heijden, et al. · European Urology Open Science · 33
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
2022 · Michiel Simon Van Der Heijden, Christopher Cutie, et al. · Journal of Clinical Oncology · 14
2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)
2023 · A. Necchi, J.W.F. Catto, et al. · Annals of Oncology · 13
PDF
SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy.
2023 · Sarah P. Psutka, Christopher Cutie, et al. · Journal of Clinical Oncology · 9
Sunrise-5: a Phase 3, Randomized, Open-label Study of Tar-200 Compared With Intravesical Chemotherapy After Bacillus Calmette-guérin in Recurrent High-risk Non–muscle-invasive Bladder Cancer
2025 · Sima Porten, Sumeet Bhanvadia, et al. · Urologic Oncology Seminars and Original Investigations · 5
SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer
2024 · J.W.F. Catto, A. Necchi, et al. · European Urology · 3
719TiP SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy
2021 · M.S. van der Heijden, C. Cutie, et al. · Annals of Oncology · 3
Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non–muscle-invasive bladder cancer: A phase 1 study.
2023 · F. Johannes P. van Valenberg, Toine van der Heijden, et al. · Journal of Clinical Oncology · 2
SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin who are ineligible for or decline radical cystectomy
2021 · M.S. Van Der Heijden, C. Cutie, et al. · European Urology Open Science · 2
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels
2025 · Benjamin Pradere, Maarten Schuit, et al. · Current Opinion in Urology · 1
Continuous Intravesical Delivery of Trospium Chloride Significantly Improves OAB Symptoms: Results of a Phase 1b Study
2019 · Christopher J. Cutie, Michael Efros, et al. · Neurourology and Urodynamics · 1
Reply by Authors
2023 · Mark D. Tyson, David Morris, et al. · The Journal of Urology
Pd21-04 Extended Continuous Intravesical Delivery of Trospium Chloride Significantly Improves Oab Symptoms Over 12 Weeks
2020 · Mitchell Effros*, Craig Herman, et al. · The Journal of Urology
Forge: Thermoelectric Cookstove
2016 · Austin Jacobs, John Maffeo, et al. · Scholar Commons (Santa Clara University)
Works count: 16
Citation count: 158
H-index: 6
I10-index: 5
Year
Topic
Type